Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > September 9, 2024
Daily News
September 9, 2024
- Takeda Sheds Working Time by 110,000 Hours via Manufacturing DX
September 9, 2024
- Mitsubishi Chemical Denies Media Report on Pharma Divestiture
September 9, 2024
- Vabysmo Filed for Label Expansion into Angioid Streaks in Japan: Chugai
September 9, 2024
- MHLW to Accept English Dossiers from Foreign Makers
September 9, 2024
- Nippon Shinyaku DMD Med Gets FDA’s Rare Pediatric Disease Tag
September 9, 2024
- MHLW Proposes Scope of Observational Research Subject to Clinical Trials Act
September 9, 2024
- Takeda’s Plasma Therapy Ceprotin Now Available in Japan
September 9, 2024
- MHLW Floats 3 Perspectives to Codify Rules for Drug Supply Management
September 9, 2024
- Japan Ethical Drug Sales Up 9.6% in July: Crecon
September 9, 2024
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…